Results 71 to 80 of about 5,230,993 (373)
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
TO THE 90TH ANNIVERSARY OF BIRTHDAY OF PROFESSOR V.G. BELIKOV
Фармация и фармакология (Пятигорск), 2015 The article is devoted to basic life milestones of Professor, Doctor of Pharmaceutical Science, Honored Scientist of Russia V.G. Belikov, who made a great contribution to the development of domestic pharmaceutical education and science, more than 30 ...
B. V. Borovsky +2 more
doaj +1 more source
Molecules, 2019 The aim of this work is to provide a critical review of plant furanocoumarins from different points of view, including their chemistry and biosynthetic pathways to their extraction, analysis, and synthesis, to the main biological activities found for ...
R. Bruni +9 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed +8 more
wiley +1 more source
Recent advances in pharmaceutical sciences VII [PDF]
, 2017 The E-book series Recent Advances in Pharmaceutical Sciences reports research contributions from different areas of the multidisciplinary field of Pharmaceutical Sciences.
Feliu José, Carlos +2 more
core
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
2018 High Sierra Leadership Expedition [PDF]
, 2018 STEP Category: Leadership2018 High Sierra Leadership Expedition Presentation by Lauren Kobasuk.The Ohio State University Second-year Transformational Experience Program (STEP)Academic Major: Pharmaceutical ...
Kobasuk, Lauren
core
Regulatory Science Ireland: bridging the information gap on biosimilar medicines [PDF]
, 2016 Regulatory Science Ireland (RSI) is a voluntary network of interested parties from academia, the Health Products Regulatory Authority (HPRA), pharmaceutical and medical device industries and government agencies.
Barry, Sean P. +6 more
core +1 more source
Heliyon, 2018 Hepatocellular cellular carcinoma (HCC) is one of the most challenging liver cancer subtypes. Due to lack of cell surface biomarkers and highly metastatic nature, early detection and targeted therapy of HCC is an unmet need.
Shaimaa Yousef +3 more
doaj
Molecular Oncology, EarlyView.Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon +13 more
wiley +1 more source